In 2023, the re-import value of Phenazone (Antipyrin) to China was significantly lower than the forecasted values for subsequent years. The projected growth from 2024 to 2028 demonstrates a gradual year-on-year increase, indicative of a rising demand or strategic shifts in trade patterns. Specifically, the forecast shows a yearly growth rate averaging at a compound annual growth rate (CAGR) in excess of previous years' figures.
Future trends to watch for include potential changes in domestic production capabilities, shifts in international trade agreements, and any regulatory impacts on pharmaceutical imports. Keeping an eye on geopolitical developments could also provide insights into further market changes.
